Mayo Clinic: Bipolar Disorder trials
The registry lists 13 Bipolar Disorder studies with Mayo Clinic as lead sponsor. 5 are open to participants now and 2 have results posted.
Early Phase 1 1Phase 1 1Phase 2 1Phase 3 1Phase 4 4No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Senyo Health App - Comorbid Alcohol Use Disorder Treatment in Individuals With Bipolar Disorder Using a Telehealth Collaborative Care PlatformNot yet recruitingNCT07556861Not applicable
- RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)RecruitingNCT07266545Phase 4
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar DisorderRecruitingNCT07213466Phase 4
- Ketogenic Intervention for Bipolar DepressionRecruitingNCT07121894Not applicable
- Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) StudyRecruitingNCT06897670
- 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar DepressionTerminatedNCT02389712Phase 4Results posted
- Bipolar Depression Before and After Lamotrigine TreatmentCompletedNCT01042496Phase 3Results posted
- 8 Week Multi-site Study of MYDAYIS® for Bipolar DepressionCompletedNCT04235686Phase 2
- Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:Active, not recruitingNCT03573349Early Phase 1
- Microbiome of Depression & Treatment Response to CitalopramCompletedNCT02330068
- Interpersonal and Social Rhythm Therapy Enter the Brief Title for Protocol IRB 09-003781>CompletedNCT01037283Not applicable
- Omega 3 Fatty Acid TrialCompletedNCT00586222Phase 1
- An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar DisorderWithdrawnNCT00221481Phase 4